State Street
ACRS icon

State Street’s Aclaris Therapeutics ACRS Stock Holding History

State Street’s Portfolio ACRS Stock Details ACRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$7.53M Buy
2,008,746
+502,343
+33% +$1.69M ﹤0.01% 2760
2025
Q4 		$4.53M Buy
1,506,403
+393,257
+35% +$994K ﹤0.01% 3036
2025
Q3 		$2.11M Buy
1,113,146
+106,253
+11% +$185K ﹤0.01% 3322
2025
Q2 		$1.43M Buy
1,006,893
+599,368
+147% +$811K ﹤0.01% 3409
2025
Q1 		$624K Buy
407,525
+88,250
+28% +$188K ﹤0.01% 3541
2024
Q4 		$792K Buy
319,275
+130,554
+69% +$325K ﹤0.01% 3534
2024
Q3 		$217K Sell
188,721
-7,900
-4% -$9.69K ﹤0.01% 3808
2024
Q2 		$216K Sell
196,621
-1,141,818
-85% -$1.34M ﹤0.01% 3799
2024
Q1 		$1.66M Sell
1,338,439
-50,000
-4% -$59.6K ﹤0.01% 3333
2023
Q4 		$1.46M Sell
1,388,439
-174,069
-11% -$531K ﹤0.01% 3398
2023
Q3 		$10.7M Buy
1,562,508
+110,524
+8% +$944K ﹤0.01% 2559
2023
Q2 		$15.1M Buy
1,451,984
+28,630
+2% +$259K ﹤0.01% 2415
2023
Q1 		$11.5M Buy
1,423,354
+120,024
+9% +$1.52M ﹤0.01% 2574
2022
Q4 		$20.5M Buy
1,303,330
+303
+0% +$4.87K ﹤0.01% 2228
2022
Q3 		$20.5M Buy
1,303,027
+72,786
+6% +$1.15M ﹤0.01% 2210
2022
Q2 		$17.2M Buy
1,230,241
+146,851
+14% +$2.06M ﹤0.01% 2360
2022
Q1 		$18.7M Buy
1,083,390
+36,000
+3% +$491K ﹤0.01% 2463
2021
Q4 		$15.2M Sell
1,047,390
-10,774
-1% -$163K ﹤0.01% 2660
2021
Q3 		$19M Sell
1,058,164
-12,050
-1% -$193K ﹤0.01% 2515
2021
Q2 		$18.8M Buy
1,070,214
+877,272
+455% +$19.9M ﹤0.01% 2558
2021
Q1 		$4.86M Buy
192,942
+114,902
+147% +$2.25M ﹤0.01% 3067
2020
Q4 		$505K Hold
78,040
– – ﹤0.01% 3644
2020
Q3 		$201K Hold
78,040
– – ﹤0.01% 3664
2020
Q2 		$126K Sell
78,040
-589,148
-88% -$789K ﹤0.01% 3645
2020
Q1 		$694K Sell
667,188
-70,210
-10% -$95.6K ﹤0.01% 3383
2019
Q4 		$1.39M Sell
737,398
-5,932
-0.8% -$9.83K ﹤0.01% 3351
2019
Q3 		$803K Buy
743,330
+136,751
+23% +$194K ﹤0.01% 3438
2019
Q2 		$1.33M Sell
606,579
-48,763
-7% -$266K ﹤0.01% 3369
2019
Q1 		$3.92M Sell
655,342
-79,341
-11% -$526K ﹤0.01% 2863
2018
Q4 		$5.43M Buy
734,683
+126,584
+21% +$1.3M ﹤0.01% 2676
2018
Q3 		$8.83M Buy
608,099
+51,454
+9% +$882K ﹤0.01% 2608
2018
Q2 		$11.1M Sell
556,645
-6,517
-1% -$120K ﹤0.01% 2488
2018
Q1 		$9.87M Buy
563,162
+73,738
+15% +$1.56M ﹤0.01% 2473
2017
Q4 		$12.1M Sell
489,424
-12,817
-3% -$312K ﹤0.01% 2373
2017
Q3 		$13M Buy
502,241
+171,486
+52% +$4.6M ﹤0.01% 2309
2017
Q2 		$8.97M Buy
330,755
+132,866
+67% +$3.61M ﹤0.01% 2451
2017
Q1 		$5.9M Buy
197,889
+27,259
+16% +$786K ﹤0.01% 2624
2016
Q4 		$4.63M Buy
170,630
+38,570
+29% +$983K ﹤0.01% 2731
2016
Q3 		$3.38M Buy
132,060
+12,050
+10% +$256K ﹤0.01% 2765
2016
Q2 		$2.22M Buy
120,010
+47,179
+65% +$935K ﹤0.01% 2993
2016
Q1 		$1.38M Buy
72,831
+28,178
+63% +$538K ﹤0.01% 3126
2015
Q4 		$1.2M Buy
+44,653
New +$870K ﹤0.01% 3177

Other funds holding ACRS

BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

State Street's ACRS Position: Q1 2026 in Review

State Street increased its Aclaris Therapeutics (ACRS) stake by 33% in Q1 2026, buying an estimated $1.69M and bringing the position to 2,008,746 shares worth $7.53M. The position accounts for ﹤0.01% of the portfolio, ranked #2760.

State Street first reported a position in ACRS in Q4 2015 and has held it in 42 quarters since. The position peaked at $20.5M in Q4 2022. 136 funds tracked by Wall St. Rank hold ACRS as of Q1 2026.

  • State Street held 2,008,746 shares of Aclaris Therapeutics worth $7.53M as of Q1 2026.
  • State Street bought 502,343 Aclaris Therapeutics shares in Q1 2026, an estimated $1.69M.
  • Aclaris Therapeutics made up ﹤0.01% of State Street's portfolio in Q1 2026, its #2760 holding.
  • State Street first reported a position in Aclaris Therapeutics in Q4 2015 and has held it in 42 quarters since.
  • State Street's Aclaris Therapeutics position peaked at $20.5M in Q4 2022.
  • 136 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q1 2026.

Based on State Street's 13F filing for Q1 2026, filed 15 May 2026.